Abstract:Objective To analyze the correlation between protein expression of X -ray repair cross complementing group 1 (XRCC1)and excision repair cross complementing 1 (ERCC1)with efficacy of concurrent radiochemotherapy(CRT)and the prognosis of patients with esophageal aquamous cell carcinoma(ESCC).Methods Immunohistochemical SP method was used to measure the protein expression of XRCC1 and ERCC in 98 ESCC tissue samples before CRT.The Kaplan -Meier method was used for survival analysis,and the log rank test was used for analyzing the survival difference between negative and positive sam-ples.The Cox model was used for multivariate prognostic analysis.Results XRCC1 and ERCC1 protein were mainly expressed in the nucleus in ESCC.There was no correlation between them (r =-0.024,P =0.811 ).The positive expression rate of XRCC1 protein in ESCC tissues and normal esophageal tissues were 57.1%(56 /98)and 13.3%(4 /30)respectively (χ2 =17.702,P =0.000).The positive expression rate of ERCC1 protein in ESCC tissues and normal esophageal tissues were 36.7%(36 /98)and 10%(3 /30)respectively(χ2 =7.749,P =0.006).The level of ERCC1 was not correlated with clinical pathologic characteristics (P >0.05).The positive expression rate of ERCC1 protein in negative lymphnode group was 44.9% (31 /69), higher than 17.2% (5 /29)in positive lymphnode group,and the difference was statistically significant (χ2 =8.183,P =0.004).The patients with positive XRCC1 expression and negative XRCC1 expression had similar short -term responses(χ2 =0.894,P =0.344)as well as similar survival rates(χ2 =0.266,P =0.606).The RR of ERCC1 negative expression group was 90.3%(56 /62),and the RR of ERCC1 positive expression group was 80.5%(29 /36),but there was no statistically significant difference (χ2 =1.888,P =0.169).The median overall survival periods of ERCC1 negative expression group was 39 months (95% CI:29.313 ~48.687 months),higher than 25 months (95% CI:18.559 ~31.441 months)in positive expression group, the difference was statistically significant (χ2 =10.174,P =0.001).In multivariate analysis,the expression of ERCC1 was closely correlated with overall survival and was the independent prognostic factor (P =0.010,95% CI:1.180 ~3.450).Conclusion ERCC1 expression was associated with the efficacy of CRT,and the patients with ERCC1 positive expression had poor prognosis.

Relationship Between ERCC1,XPC Proteins and Curative Effect of Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancers

Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Increased ERCC1 Protein Expression is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer.

Profiling Protein Markers Associated with the Sensitivity to Concurrent Chemoradiotherapy in Human Cervical Carcinoma.

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Quantitative Proteomics Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers

Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation

ERCC1 and BRCA1 Expressions in the Tissues of Colorectal Cancer and Its Relationship with Clinical Significance of Platinum-Based Chemotherapy

Analysis of correlation between protein expression of XRCC1 and ERCC1 with efficacy of concurrent radiochemotherapy and the prognosis of patients with esophageal aquamous cell carcinoma

Estrogen Receptor-Related Genes As An Important Panel Of Predictors For Breast Cancer Response To Neoadjuvant Chemotherapy

Relationship Between Expression of ERCC1 and Effect of Platinum-based Chemotherapy in Patients with Advanced NSCLC

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Expression of excision repair cross-complementation group 1 in non-small-cell lung cancer and its contribution to Cisplatin-based adjuvant chemotherapy

Meta-Analysis of Predictive Value of ERCC1 Protein Expression in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy